The role of basiliximab in the evolving renal transplantation immunosuppression protocol

References

• AcottPDLawenJLeeS2001Basiliximab versus ATG/ALG induction in pediatric renal transplants: comparison of herpes virus profile and rejection ratesTransplant Proc333180311750365
   PubMed Web of Science ®Google Scholar
• AduDCockwellPIvesNJ2003Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomised trialsBMJ3267899112689974
   PubMed Web of Science ®Google Scholar
• Al NajjarAEtienneILe PogampP2006Long-term results of monoclonal anti-IL2-receptor antibody versus polyclonal antilymphocyte antibodies as induction therapy in renal transplantationTransplant Proc382298916980070
   PubMed Web of Science ®Google Scholar
• AmlotPLRawlingsEFernandoON1995Prolonged action of a chimeric interleukin-2 receptor (CD25) monoclonal antibody used in cadaveric renal transplantationTransplantation60748567570988
   PubMed Web of Science ®Google Scholar
• Anil KumarMSSierkaDRDamaskAM2005Safety and success of kidney transplantation and concomitant immunosuppression in HIV-positive patientsKidney Int671622915780120
   PubMed Web of Science ®Google Scholar
• AuchinlossHJr1995Antigen presentationBachFHAuchinlossHJrTransplantation ImmunologyNew YorkWiley-Liss958
   Google Scholar
• AwMMTaylorRMVermaA2003Basiliximab (Simulect) for the treatment of steroid-resistant rejection in pediatric liver transplant recipients: a preliminary experienceTransplantation75796912660504
   PubMed Web of Science ®Google Scholar
• BaanCCvan der MastBJKlepperM2005Differential effect of calcineurin inhibitors, anti-CD25 antibodies and rapamycin on the induction of FOXP3 in human T cellsTransplantation801101716003241
   PubMed Web of Science ®Google Scholar
• BasadonnaGPMatasAJGillinghamKJ1993Early versus late acute renal allograft rejection: impact on chronic rejectionTransplantation5599358497913
   PubMed Web of Science ®Google Scholar
• BaudouinVCrusiauxAHaddadE2003Anaphylactic shock caused by immunoglobulin E sensitization after retreatment with the chimeric anti-interleukin-2 receptor monoclonal antibody basiliximabTransplantation764596312923429
   PubMed Web of Science ®Google Scholar
• BoggiUDanesiRVistoliF2004A benefit-risk assessment of basiliximab in renal transplantationDrug Safety279110614717621
   PubMed Web of Science ®Google Scholar
• BrennanDC2003Thymoglobulin versus Simulect for induction immunosuppression in cadaveric renal transplant recipients: expanded results from a prospective, randomized, multicenter trialAm J Transplant5Suppl 34389
   Google Scholar
• BrennanDCDallerJALakeKD2006Rabbit antithymocyte globulin versus basiliximab in renal transplantationN Engl J Med35519677717093248
   PubMed Web of Science ®Google Scholar
• BrentL1997A History of Transplantation ImmunologySan Diego: Acad Pr, Inc31920
   Google Scholar
• ChanLCooperMLeventhalJ2006Excellent renal function at 6 months in de novo kidney transplant recipients treated with everolimus, basiliximab and reduced tacrolimus exposureTransplantation82Suppl 3299300
   Google Scholar
• ChapmanTMKeatingGM2003Basiliximab: a review of its use as induction therapy in renal transplantationDrugs6328033514664658
   PubMed Web of Science ®Google Scholar
• ChariatMNErrenMChariatM2001Basiliximab in the therapy of acute rejection after organ transplantationTransplant Proc33238011377567
   PubMed Web of Science ®Google Scholar
• ChilcottJBHolmesMWWaltersS2002The economics of basiliximab (Simulect) in preventing acute rejection in renal transplantationTransplant Int1548693
   PubMed Web of Science ®Google Scholar
• ChowdhurySKodeRKRangannaK2001Induction strategy using basiliximab combined with mycophenolate MMF and immediate low-dose cyclosporin is steroid sparing and more effective than OKT3Transplant Proc331057811267189
   PubMed Web of Science ®Google Scholar
• ChurchAC2003Clinical advances in therapies targeting the interleukin-2 receptorQ J Med9691102
   Google Scholar
• ClarkGWalshGDeshpandeP2002Improved efficacy of basiliximab over antilymphocyte globulin induction therapy in paediatric renal transplantationNephrol Dial Transplant171304912105256
   PubMed Web of Science ®Google Scholar
• CromptonJASomervilleTSmithL2003Lack of economic benefit with basiliximab induction in living related donor adult renal transplant recipientsPharmacother2344350
   PubMed Web of Science ®Google Scholar
• de BoccardoG2002Latin American study of the efficacy and safety of Simulect in kidney transplant recipientsTransplantation74467
   Google Scholar
• EguchiSYanagaKOkudairaS2004Immunodynamics of basiliximab in liver allograft recipient under continuous hemodiafiltrationTransplantation771477815167617
   PubMed Web of Science ®Google Scholar
• EmparanCLaukötterMWoltersH2003Calcineurin-free protocols with basiliximab induction allow patients included in “old-to-old” programs to achieve standard kidney transplant functionTransplant Proc351326712826150
   PubMed Web of Science ®Google Scholar
• GameDSHernandez-FuentesMPLechlerRI2005Everolimus and basiliximab permit suppression by human CD4+CD25+ cells in vitroAm J Transplant54546415707399
   PubMed Web of Science ®Google Scholar
• GohHKLyeWC2001Biopsy-proven resolution of steroid-resistant acute rejection with basiliximab therapy in a renal allograft recipientTransplant Proc3332131411750379
   PubMed Web of Science ®Google Scholar
• GrendaRWatsonAVondrakK2006A prospective, randomized, multicenter trial of tacrolimus-based therapy with or without basiliximab in pediatric renal transplantationAm J Transplant616667216827869
   PubMed Web of Science ®Google Scholar
• HagenmeyerE-GHausslerBHempelE2004Resource use and treatment costs after kidney transplantation: impact of demographic factors, comorbidities and complicationsTransplantation7715455015239619
   PubMed Web of Science ®Google Scholar
• HamdyAFEl-AgroudyAEBakrMA2005Comparison of sirolimus with low-dose tacrolimus versus sirolimus-based calcineurin inhibitor-free regimen in live donor renal transplantationAm J Transplant52531816162204
   PubMed Web of Science ®Google Scholar
• HaririanAMorawskiKSillixDH2005Induction therapy with basiliximab versus thymoglobulin in African-American kidney transplant recipientsTransplantation797162115785379
   PubMed Web of Science ®Google Scholar
• HeifetsMSaeedMIParikhMH2004Induction immunosuppression in kidney transplant recipients older that 60 years of age: safety and efficacy of ATGAM®, OKT3® and Simulect®Drugs Aging217475615323580
   PubMed Web of Science ®Google Scholar
• HongJCKahanBD2001A calcineurin antagonist-free induction strategy for immunosuppression in cadaveric kidney transplant recipients at risk for delayed graft functionTransplantation711320811397971
   PubMed Web of Science ®Google Scholar
• JirasirithamSSumethkulVMavichakV2004The role of anti-IL-2 receptor in high-risk kidney transplant patientsTransplant Proc3621101215518764
   PubMed Web of Science ®Google Scholar
• KahanBDRajagopalanPRHallM1999Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study GroupTransplantation672768410075594
   PubMed Web of Science ®Google Scholar
• KaufmanDBLeventhalJRAxelrodD2005Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: comparison with basiliximab induction – long-term resultsAm J Transplant525394816162205
   PubMed Web of Science ®Google Scholar
• KeownPABalshawRKhorashehS2003Meta-analysis of basi-liximab for immunoprophylaxis in renal transplantationBiodrugs17271912899644
   PubMed Web of Science ®Google Scholar
• KnightRJKermanRHSchoenbergL2004The selective use of basiliximab versus thymoglobulin in combination with sirolimus for cadaveric renal transplant recipients at low risk versus high risk for delayed graft functionTransplantation789041015385812
   PubMed Web of Science ®Google Scholar
• KodeRFaKChowdhuryS2003Basiliximab plus low-dose cyclosporin vs OKT3 for induction immunosuppression following renal transplantationClin Transplant173697612868995
   PubMed Web of Science ®Google Scholar
• KovarikJMRawlingsESwenyP1996Pharmacokinetics and immunodynamics of chimeric IL-2 receptor monoclonal antibody SDZ CHI 621 in renal allograft recipientsTransplant Int9Suppl 1S3233
   PubMedGoogle Scholar
• KovarikJWolfPCisterneJM1997Disposition of basiliximab, an interleukin-2 receptor monoclonal antibody, in recipients of mismatched cadaver renal allograftsTransplantation64170159422405
   PubMed Web of Science ®Google Scholar
• KovarikJMKahanBDRajagopalanPR1999Population pharmacokinetics and exposure-response relationships for basiliximab in kidney transplantationTransplantation6812889410573065
   PubMed Web of Science ®Google Scholar
• KovarikJMPescovitzMDSollingerHW2001Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patientsClin Transplant151233011264639
   PubMed Web of Science ®Google Scholar
• KovarikJMOffnerGBroyerM2002A rational dosing algorithm for basiliximab (Simulect) in pediatric renal transplantation based on pharmacokinetic-dynamic evaluationsTransplantation749667112394838
   PubMed Web of Science ®Google Scholar
• KoyamaIFuchinoneSIwadoK2006Steroid can be safely withdrawn in ABO-incompatible kidney transplant recipients by using basiliximabTransplantation82Suppl 351616926596
   PubMed Web of Science ®Google Scholar
• KumarAMSFaKVankawalaR2001Simulect, calcineurin inhibitor, mycophenolate mofetil, and prednisone is more effective than OKT3, calcineurin inhibitor, mycophenolate mofetil, and prednisone in African American kidney recipients in reducing acute rejections and prolonging graft survivalTransplant Proc333195611750370
   PubMed Web of Science ®Google Scholar
• KumarMSAXiaoS-GFyfeB2004Steroid avoidance in renal transplantation using basiliximab induction, cyclosporine-based immunosuppression and protocol biopsiesClin Transplant1961915659136
   PubMed Web of Science ®Google Scholar
• LawenJGDaviesEAMouradG2003Randomized double-blind study of immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with mycophenolate mofetil-containing triple therapy in renal transplantationTransplantation75374312544868
   PubMed Web of Science ®Google Scholar
• LebranchuYBridouxFBuchlerM2002Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapyAm J Transplant2485612095056
   PubMed Web of Science ®Google Scholar
• LeggatJEOjoAOLeichtmanAB1997Long-term renal allograft survival: prognostic implication of the timing of acute rejection episodesTransplantation631268729158020
   PubMed Web of Science ®Google Scholar
• LeonardiGMessinaMGiraudiR2004Basiliximab in association with tacrolimus and steroids in caucasian cadaveric renal transplanted patients: significant decrease in early acute rejection rate and hospitalization timeClin Transplant181131815016122
   PubMed Web of Science ®Google Scholar
• LorberMIFastenauJWilsonD2000A prospective economic evaluation of basiliximab (Simulect®) therapy following renal transplantationClin Transplant144798511048993
   PubMed Web of Science ®Google Scholar
• Martinez-MierGMendez-LopezMTBudar-FernandezLF2006Living related kidney transplantation without calcineurin inhibitors: initial experience in a Mexican centerTransplantation821533617164728
   PubMed Web of Science ®Google Scholar
• Meier-KriescheH-ULiSGruessnerRWG2006Immunosuppression: evolution in practice and trends, 1994–2004Am J Transplant6Part 211113116613591
   PubMed Web of Science ®Google Scholar
• MorrisJCWaldmannTA2000Advances in interleukin 2 receptor targeted treatmentAnn Rheum Dis59Suppl Ii1091411053100
   PubMed Web of Science ®Google Scholar
• MouradGRostaingLLegendreC2004Sequential protocols using basiliximab versus anti-thymocyte globulins in renal-transplant patients receiving mycophenolate mofetil and steroidsTransplantation785849015446319
   PubMed Web of Science ®Google Scholar
• NagaiTGotoYHabaT2005The effect of urinary protein excretion in post-renal transplant recurrent nephrotic syndrome on basiliximab pharmacokinetics and pharmacodynamics in a pediatric patientTransplant Proc378798015848562
   PubMed Web of Science ®Google Scholar
• NashanBMooreRAmlotP1997Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study GroupLancet350908611931198(Erratum in: Lancet, 1997. 350(9089):1484.)9652559
   PubMed Web of Science ®Google Scholar
• NojimaMYoshimotoTNakaoA2005Sequential blood level monitoring of basiliximab during multisession plasmapheresis in a kidney transplant recipientTransplant Proc37875815848561
   PubMed Web of Science ®Google Scholar
• OffnerGHoeckerBPapeL2006A multicenter, placebo controlled trial evaluating the efficacy and safety of basiliximab (Simulect®) in combination with CsA, MMF and steroids in pediatric renal allograft recipients, 12 months resultsTransplantation82Suppl 399
   Google Scholar
• OjoghoOSahneySCutlerD2005Mycophenolate mofetil in pediatric renal transplantation: non-induction vs induction with basiliximabPediatr Transplant980315667617
   PubMed Web of Science ®Google Scholar
• OkechukwuCNMeier-KriescheH-UArmstrongD2001Removal of basiliximab by plasmapheresisAm J Kidney Dis37E1111136200
   PubMed Web of Science ®Google Scholar
• PalletNAnglicheauDMartinezF2006Comparison of sequential protocol using basiliximab versus antithymocyte globulin with high-dose mycophenolate mofetil in recipients of a kidney graft from an expanded-criteria donorTransplantation819495216570022
   PubMed Web of Science ®Google Scholar
• PapeLStrehlauJHenneT2002Single centre experience with basiliximab in paediatric renal transplantationNephrol Dial Transplant172768011812879
   PubMed Web of Science ®Google Scholar
• ParrottNRHammadAQWatsonCJE2005Multicenter, randomized study of the effectiveness of basiliximab in avoiding addition of steroids to cyclosporine A monotherapy in renal transplant recipientsTransplantation79344815699766
   PubMed Web of Science ®Google Scholar
• PascualJMarcénROrtuñoJ2001Anti-interleukin-2 receptor antibodies: basiliximab and daclizumabNephrol Dial Transplant1617566011522853
   PubMed Web of Science ®Google Scholar
• PelletierRPDaviesEAElkhammasEA2000Improved outcome in renal transplant recipients treated with Simulect versus OKT3 inductionTransplantation69S157
   PubMedGoogle Scholar
• PonticelliCYussimACambiV2001A randomized, double-blind trial of basiliximab immunoprophylaxis plus triple therapy in kidney transplant recipientsTransplantation721261711602853
   PubMed Web of Science ®Google Scholar
• QueenCSchneiderWPSelickHE1989A humanized antibody that binds to the interleukin-2 receptorProc Natl Acad Sci USA8610029332513570
   PubMed Web of Science ®Google Scholar
• RamirezCBMarinoIR2007The role of basiliximab induction therapy in organ transplantationExpert Opin Biol Ther71374817150025
   PubMed Web of Science ®Google Scholar
• SakaguchiS2005Naturally arising Foxp3-expressing CD25+CD4+ regulatory T cells in immunological tolerance to self and non-selfNature Immunol63455215785760
   PubMed Web of Science ®Google Scholar
• SandriniS2005Use of IL-2 receptor antagonists to reduce delayed graft function following renal transplantation: a reviewClin Transplant197051016313313
   PubMed Web of Science ®Google Scholar
• SchenaFPVincentiFParaskevasS200612-month results of a prospective, randomized trial of steroid avoidance, steroid withdrawal and standard steroids in de novo renal transplant patients receiving cyclosporine, enteric-coated mycophenolate sodium (EC-MPS, myfortic®) and basiliximabTransplantation82suppl 3845
   Google Scholar
• SheashaaHABakrMAIsmailAM2003Basiliximab reduces the incidence of acute cellular rejection in live related donor kidney transplantation: a three-year prospective randomized trialJ Nephrol16393812832740
   PubMed Web of Science ®Google Scholar
• SheashaaHABakrMAIsmailAM2005Long-term evaluation of basiliximab induction therapy in live donor kidney transplantation: a five-year prospective randomized studyAm J Nephrol25221515908741
   PubMed Web of Science ®Google Scholar
• ShoskesDAFlechnerSMShoskesVL2006A randomized prospective trial of OKT3 vs basiliximab induction in renal transplantation with over 5 year follow upTransplantation82Suppl 349416926593
   PubMed Web of Science ®Google Scholar
• SifontisNMBenedettiEVasquezEM2002Clinically significant drug interaction between basiliximab and tacrolimus in renal transplant recipientsTransplant Proc341730212176554
   PubMed Web of Science ®Google Scholar
• SolaRAlarconAJimenez2004The influence of delayed graft functionNephrol Dial Transplant19Suppl 3iii32715192133
   PubMedGoogle Scholar
• SollingerHKaplanBPescovitzMD2001Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejectionTransplantation7219151911773888
   PubMed Web of Science ®Google Scholar
• SollingerHWOdoricoJSBeckerYT2006Campath vs basiliximab after simultaneous pancreas-kidney transplantation in 331 patientsTransplantation82Suppl 3103
   Google Scholar
• SterkersGBaudouinVAnsart-PirenneH2000Duration of action of a chimeric interleukin-2 receptor monoclonal antibody, basiliximab, in pediatric kidney transplant recipientsTransplant Proc322757911134788
   PubMed Web of Science ®Google Scholar
• StrehlauJPapeLOffnerG2000Interleukine-2 receptor antibody-induced alterations of ciclosporin dose requirements in paediatric transplant recipientsLancet3561327811073027
   PubMed Web of Science ®Google Scholar
• Swiatecka-UrbanAGarciaCFeuersteinD2001Basiliximab induction improves the outcome of renal transplants in children and adolescentsPediatr Nephrol16693611511978
   PubMed Web of Science ®Google Scholar
• Swiatecka-UrbanA2003Anti-interleukin-2 receptor antibodies for the prevention of rejection in pediatric renal transplant patients: current statusPediatr Drugs5699716
   PubMedGoogle Scholar
• TanJYangSWuW2005Basiliximab (Simulect) reduces acute rejection among sensitized kidney allograft recipientsTransplant Proc37903515848570
   PubMed Web of Science ®Google Scholar
• ThistlethwaiteJRJrNashanBHallM2000Reduced acute rejection and superior 1-year renal allograft survival with basiliximab in patients with diabetes mellitus. The Global Simulect Study GroupTransplantation707849011003358
   PubMed Web of Science ®Google Scholar
• UchiyamaTNelsonDLFleisherTA1981A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T-cellsJ Immunol12613984036451645
   PubMed Web of Science ®Google Scholar
• VesterUKranzBTestaG2001Efficacy and tolerability of interleukin-2 blockade with basiliximab in pediatric renal transplant recipientsPediatr Transplant529730111472610
   PubMed Web of Science ®Google Scholar
• VincentiFMonacoAGrinyoJ2003Multicenter randomized prospective trial of steroid withdrawal in renal transplant recipients receiving basiliximab, cyclosporin microemulsion and mycophenolate mofetilAm J Transplant33061112614286
   PubMed Web of Science ®Google Scholar
• VincentiF2004Interleukin-2 receptor antagonists and aggressive steroid minimization strategies for kidney transplant patientsTransplant Int17395401
   PubMed Web of Science ®Google Scholar
• VincentiFSchenaFPParaskevasS2006Metabolic effects of steroid avoidance or early steroid withdrawal: 12-month results of a randomized trial in de novo renal transplant patients receiving cyclosporine, enteric-coated mycophenolate sodium (EC-MPS) and basiliximabTransplantation82Suppl 3483
   Google Scholar
• VìtkoSKlingerMSalmelaK2005Two corticosteroid-free regimens – tacrolimus monotherapy after basiliximab administration and tacrolimus/mycophenolate mofetil – in comparison with a standard triple regimen in renal transplantation: results of the Atlas StudyTransplantation8017344116378069
   PubMed Web of Science ®Google Scholar
• WaltersSJWhitfieldMAkehurstRL2003Economic implications of the use of basiliximab in addition to triple immunosuppressive therapy in renal allograft recipients: a UK perspectivePharmacoeconomics211293812515574
   PubMed Web of Science ®Google Scholar
• WebsterACPlayfordEGHigginsG2004Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trialsTransplantation771667614742976
   PubMed Web of Science ®Google Scholar
• WoodleESVincentiFLorberMI2005A multicenter pilot study of early (4-day) steroid cessation in renal transplant recipients under Simulect, tacrolimus and sirolimusAm J Transplant51576615636625
   PubMed Web of Science ®Google Scholar
• XiaoSGLeeDFyfeB2003Two-year patient and graft survival, graft function and chronic allograft nephropathy with steroid-free Neoral based immunosuppression in kidney transplant recipients – a controlled studyAm J Transplant53 Suppl440
   Google Scholar